- Home
- EXAS vs TXRH Comparison
EXAS vs TXRH Comparison
Compare EXAS & TXRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- TXRH
- Stock Information
- Founded
- EXAS 1995
- TXRH 1993
- Country
- EXAS United States
- TXRH United States
- Employees
- EXAS N/A
- TXRH N/A
- Industry
- EXAS Medical Specialities
- TXRH Restaurants
- Sector
- EXAS Health Care
- TXRH Consumer Discretionary
- Exchange
- EXAS Nasdaq
- TXRH Nasdaq
- Market Cap
- EXAS 10.7B
- TXRH 11.4B
- IPO Year
- EXAS N/A
- TXRH 2004
- Fundamental
- Price
- EXAS $56.13
- TXRH $194.67
- Analyst Decision
- EXAS Strong Buy
- TXRH Buy
- Analyst Count
- EXAS 20
- TXRH 21
- Target Price
- EXAS $70.68
- TXRH $191.62
- AVG Volume (30 Days)
- EXAS 3.3M
- TXRH 1.1M
- Earning Date
- EXAS 07-30-2025
- TXRH 05-08-2025
- Dividend Yield
- EXAS N/A
- TXRH 1.40%
- EPS Growth
- EXAS N/A
- TXRH 30.91
- EPS
- EXAS N/A
- TXRH 6.48
- Revenue
- EXAS $2,828,128,000.00
- TXRH $5,499,763,000.00
- Revenue This Year
- EXAS $14.58
- TXRH $11.10
- Revenue Next Year
- EXAS $12.75
- TXRH $8.89
- P/E Ratio
- EXAS N/A
- TXRH $30.04
- Revenue Growth
- EXAS 11.57
- TXRH 15.09
- 52 Week Low
- EXAS $39.97
- TXRH $148.73
- 52 Week High
- EXAS $72.83
- TXRH $206.04
- Technical
- Relative Strength Index (RSI)
- EXAS 60.75
- TXRH 64.92
- Support Level
- EXAS $55.26
- TXRH $186.52
- Resistance Level
- EXAS $58.68
- TXRH $199.99
- Average True Range (ATR)
- EXAS 1.99
- TXRH 4.01
- MACD
- EXAS -0.27
- TXRH 0.17
- Stochastic Oscillator
- EXAS 62.66
- TXRH 60.50
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
About TXRH Texas Roadhouse Inc.
Texas Roadhouse Inc is a restaurant company operating predominantly in the casual dining segment. The company manages its restaurant and franchising operations by concept and, as a result, has identified Texas Roadhouse, Bubba's 33, Jaggers, and retail initiatives as separate operating segments. In addition, it has identified Texas Roadhouse and Bubba's 33 as reportable segments. Maximum revenue for the company is generated from the Texas Roadhouse segment, which is a moderately priced, full-service, casual dining restaurant concept offering steaks, a selection of ribs, seafood, chicken, pork chops, pulled pork, vegetable plates, and an assortment of hamburgers, salads, and sandwiches.